Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
52,253,997
-
Shares change
-
+311,469
-
Total reported value, excl. options
-
$30,149,698
-
Value change
-
+$763,514
-
Put/Call ratio
-
25%
-
Number of buys
-
21
-
Number of sells
-
-48
-
Price
-
$0.5770
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2022
97 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2022.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52,253,997 shares
of 236,234,693 outstanding shares and own 22% of the company stock.
Largest 10 shareholders include Alerce Investment Management, L.P. (15,090,119 shares), VANGUARD GROUP INC (11,238,870 shares), ACADIAN ASSET MANAGEMENT LLC (7,483,053 shares), BlackRock Inc. (2,922,544 shares), RENAISSANCE TECHNOLOGIES LLC (2,886,227 shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2,014,767 shares), GEODE CAPITAL MANAGEMENT, LLC (1,682,498 shares), MILLENNIUM MANAGEMENT LLC (1,342,422 shares), FEDERATED HERMES, INC. (1,020,032 shares), and FMR LLC (613,590 shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.